ライフサイエンスコーパス: treatment period

1 eriod (approximately the last 8 weeks of the treatment period).

2 ulation (all patients who completed all four treatment periods).

3 r both in combination, for the core 12-month treatment period.

4 per day orally during a 12-week double-blind treatment period.

5 o received methotrexate for the full 52 week treatment period.

6 by week 2 and were sustained throughout the treatment period.

7 sities did not change significantly over the treatment period.

8 hree dose levels with placebo over a 52-week treatment period.

9 editary angio-oedema observed in each 4 week treatment period.

10 in glargine U100 were also seen for the full treatment period.

11 e of antidrug antibodies detected during the treatment period.

12 ortin-positive neuroblasts at the end of the treatment period.

13 articipants, of whom 96 completed the 6-week treatment period.

14 in estimated GFR (eGFR) trajectory over the treatment period.

15 e to a significant degree over the rituximab treatment period.

16 ts who reported a fracture event in the post-treatment period.

17 = 35; placebo, n = 33) completed the 28-week treatment period.

18 entage of patients who completed the 24-week treatment period.

19 ed disability progression in the prebaseline treatment period.

20 aseline and 15.8 (5.6-57.6) over the 12 week treatment period.

21 in part B, 33 of whom completed the 24 week treatment period.

22 nstant was 0.033+/-0.009mm(3)/day during the treatment period.

23 cortisone in vasovagal syncope over a 1-year treatment period.

24 ne, for 2 or more weeks during a 4-week post-treatment period.

25 95% CI, -4.6 to -0.2) 7 to 14 days after the treatment period.

26 e response sustained response throughout the treatment period.

27 ct of caplacizumab was maintained during the treatment period.

28 nd similar between treatments over the whole treatment period.

29 , assessed 7 to 14 days after the end of the treatment period.

30 ared with enalapril, over a relatively short treatment period.

31 ore or preserve SGC function well beyond the treatment period.

32 No serious AEs were reported during the treatment period.

33 tive treatment or placebo (3:1) for a 12-day treatment period.

34 ebulizer) were each followed by a 4-week off-treatment period.

35 ntidepressant treatment with a preceding non-treatment period.

36 The patient remained asymptomatic during the treatment period.

37 d, and a 3-week wash out separated each drug treatment period.

38 then remained stable throughout the complete treatment period.

39 he primary outcome was live birth during the treatment period.

40 ine, and tumor sizes were monitored over the treatment period.

41 ady increase in body weight of mice over the treatment period.

42 be taken at mealtimes twice daily during the treatment period.

43 etion and cholesterol efflux over the 14-day treatment period.

44 e resolved effect kinetics over the complete treatment period.

45 ium spp. populations was observed during the treatment period.

46 this trend was sustained throughout the 28-d treatment period.

47 group and the placebo group over the 6-month treatment period.

48 ng beta-agonists were not allowed during the treatment period.

49 ulin sensitivity before and after the 6-week treatment period.

50 experienced by adolescents during the cancer treatment period.

51 0 mg BID or prasugrel 10 mg OD with a 15-day treatment period.

52 S:Inv) Total score at the end of each 4-week treatment period.

53 was given for the first 4 to 6 weeks of each treatment period.

54 to symptoms in adolescents during the cancer treatment period.

55 le (FAS) before, during, and after a 3-month treatment period.

56 sease Activity Index <150) at the end of the treatment period.

57 y was reduced from baseline over the 24-week treatment period.

58 roughout a 10 min pre-treatment and a 10 min treatment period.

59 r, or retinal detachment during the 12-month treatment period.

60 mmediately, 3 months, and 6 months after the treatment period.

61 fusion mean hemoglobin levels throughout the treatment period.

62 bined score during 4 weeks at the end of the treatment period.

63 tor-confirmed HAE attacks during the 24-week treatment period.

64 ve and ductal carcinoma in situ) in the post-treatment period.

65 tarting value and was maintained through the treatment period.

66 osphate concentration towards the end of the treatment period.

67 e number of migraine days during the 12-week treatment period.

68 us ivacaftor group) and completed the 4-week treatment period.

69 occurrence of severe neutropenia during the treatment period.

70 on on repeat imaging at the end of the study treatment period.

71 co-treated with prednisolone over an 8 week treatment period.

72 ow the toxic threshold limit over the entire treatment period.

73 ic function that persisted beyond the pacing treatment period.

74 costeroid-naive individuals over an 18-month treatment period.

75 ated risk of death, particularly in the post-treatment period.

76 from cerebral ischemia after the end of the treatment period.

77 in the placebo group discontinued during the treatment period.

78 in part B, 56 of whom completed the 24-week treatment period.

79 esponders) were included in the double-blind treatment period.

80 relatively healthy older adults over a 24-mo treatment period.

81 Safety was recorded over the 6-month treatment period.

82 142 participants had follow-up data in both treatment periods.

83 of hot flushes during the final week of both treatment periods.

84 kg/h) and risperidone (0.001-0.0056 mg/kg/h) treatment periods.

85 ht-fasted subjects before and after the 6-mo treatment periods.

86 essed by questionnaire at the end of the two treatment periods.

87 ged 3-219 months) were much the same between treatment periods.

88 eriod, with a 28-day washout between the two treatment periods.

89 All patients completed both treatment periods.

90 Both TIE and TRD decrease with increasing treatment periods.

91 sychological evaluation during the late post-treatment period (1.3-4 years post diagnosis), assessing

92 116 patients who completed the double-blind treatment period, 111 entered the open-label extension s

93 Risk differences during the randomized treatment period (12 to 30 months) for ischemic (MI and/

94 irst 12 months of the VBP15-LTE trial (total treatment period 18 months).

95 Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 months

96 During the 24-week treatment period, 2 (2.9%), 3 (3.4%), 0, and 4 (5.0%) pa

97 NK cells in blood and tissues throughout the treatment period; 2) substantial, albeit transient, depl

98 At the end of the 12-week treatment period, 62% of patients who received the 800-m

99 During the 24-week open-label treatment period, 70 [80%] of 87 patients achieved plate

100 If a patient was discharged during the treatment period, a treatment based on the last measured

101 s allocated, for the duration of the 52-week treatment period administered by daily subcutaneous inje

102 Across the 12-week treatment period, all five atogepant groups showed signi

103 During the treatment period, all the patients tested negative for T

104 During the initial 8-week treatment period, all three treatment groups experienced

105 he placebo group; at 42 to 56 days after the treatment period, an invasive infection had developed in

106 e-chain-reaction (rt-PCR) assays, during the treatment period and 10 months after the end of treatmen

107 0-fold lower than baseline during the 3 year-treatment period and 10-fold lower during the follow-up

108 multinational clinical trial with a 24-week treatment period and 28-week follow-up conducted between

109 le-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enro

110 ebo-controlled clinical trial with a 12-week treatment period and a further 12-week follow-up conduct

111 ovement in quality of life at the end of the treatment period and a reduction in the number of severe

112 and the ASRS, before and during the 3-month treatment period and after a 1-month washout period.

113 were monitored for adverse events during the treatment period and assessed for combined rhinoconjunct

114 imaging was obtained at the end of the main treatment period and compared with baseline imaging test

115 d in part A, 11 of whom completed the 15-day treatment period and enrolled in part B.

116 Ten patients completed a 6 month treatment period and entered the extension phase; nine r

117 ed multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted

118 th peak was maintained throughout the 3-year treatment period and for 2 years after discontinuation.

119 events that occurred or worsened during the treatment period and had a frequency of 5% or more or we

120 Findings were consistent during the on-treatment period and in those with incidental VTE.

121 ntly observed clonal shifts during the early treatment period and its potential association with adve

122 take; however, the effect decreased over the treatment period and rapidly disappeared when drug treat

123 on outcomes were assessed during the 3-month treatment period and the 3-month follow-up period.

124 ssessed over 24 weeks, including the 12-week treatment period and the subsequent 12 weeks after study

125 compounds produced tumour stasis during the treatment period and upon cessation of treatment, tumour

126 was annualised relapse rate (ARR) during the treatment period and was assessed in the intention-to-tr

127 A longer treatment period and/or a higher dose may improve the cl

128 tilised lasting 42 weeks, with three 10-week treatment periods and two 6-week washout periods.

129 33 patients completed all four treatment periods and were included in the primary outco

130 f the study, all of whom completed the 4 day treatment period, and eight of whom took part in part B.

131 n-in period, concurrent treatment during the treatment period, and instrument version significantly i

132 etastatic disease remained stable during the treatment period, and no other site of metastatic diseas

133 es rainfall and temperature covariates, drug treatment periods, and population variability is capable

134 of TTP, or a thromboembolic event during the treatment period; and a lower rate of recurrence of TTP

135 At the end of the treatment period, animals were tested for locomotor acti

136 maximum preinjection IOP during the 24-month treatment period; any occurrence of absolute preinjectio

137 years of cessation of immunotherapy (3-year treatment period) are linked to the acquisition and main

138 convulsive-seizure frequency over a 14-week treatment period, as compared with a 4-week baseline per

139 In the 4-week post-treatment period, ascending dose cohorts underwent a fur

140 IOP was measured at the end of each treatment period at 4, 6, and 8 pm.

141 g better quality of life), at the end of the treatment period at week 14, after the 2-week course of

142 ears; 57 women [63%]), 56 had completed both treatment periods at the time of the study's termination

143 n at index, number of seasonal cycles within treatment period, baseline AR/asthma treatment prescript

144 (weeks 0-156), a 56% reduction from the off-treatment period between DREAM and COLUMBA.

145 The off-treatment period between INPULSIS and INPULSIS-ON could

146 After the 4-week treatment period, both groups were brought back to under

147 ined SSA disability benefits over the 2-year treatment period, but there were also some unintended ad

148 The microbiota was then subjected to a 4-wk treatment period by adding 5 mL of sterile peptone water

149 placebo run-in period with values in the ICS treatment period by using paired t tests.

150 At the end of each treatment period, CBFV by transthoracic Doppler echocard

151 nnualized severe exacerbation rates over the treatment period, changes from baseline in pre-BD FEV(1)

152 ilar across groups (neoadjuvant and adjuvant treatment periods combined).

153 al was 90.9% (83.5%-99%) over the biological treatment period compared with 58.7% (43.3%-79.7%; P=0.0

154 frequency of convulsive seizures during the treatment period compared with baseline in the 0.7 mg/kg

155 icantly less functional impairment after the treatment period compared with patients with normal base

156 re significantly reduced during the anakinra treatment period compared with those seen after placebo.

157 es were lower during the combined idelalisib treatment periods compared with placebo (treatment diffe

158 The planned 8-week treatment period could be shortened or extended if neede

159 ted freedom from PGTCS at end of the 24-week treatment period (day 166) for lacosamide/placebo was 31

160 ffects of OC000459 persisted into the second treatment period despite a 3-week washout phase.

161 oncentration increased (p < 0.01) during the treatment period, due mainly to significant increased le

162 At the end of the treatment period, each animal was sedated with propofol

163 nuary 2014-January 12, 2016) for two 32-week treatment periods, each with a 16-week titration and a 1

164 target crossover trial including two 32-week treatment periods, each with a 16-week titration period

165 At the end of a 10-week treatment period, echocardiography revealed reduced card

166 crossover design, each involving two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per k

167 6 common symptoms in adolescents during the treatment period: fatigue, sleep-wake disturbances, naus

168 ed From AMD Parents [LIMPIA]) with a 6-month treatment period, followed by a 6-month follow-up period

169 memantine (MEM; 20 mg/day), during the first treatment period, following which they completed ADP2.

170 atment they did not receive during the first treatment period, following which they completed ADP3.

171 reached maximal levels on day 2 of the post-treatment period for both doses (mug kg(-)(1)): 5920 and

172 y monitoring during the 5-year pharmacologic treatment period for osteoporosis in women.

173 Patients were seen weekly during a 4-week treatment period for safety assessments, best-corrected

174 d of open-label inhaled fluticasone, and the treatment periods for subjects randomized to (1) continu

175 ferences were also observed for the combined treatment periods for total symptom scores, nasal airflo

176 13 in the chemotherapy group died during the treatment period (from the day of the first dose of stud

177 However, challenges include long treatment periods, high rates of adverse reactions, and

178 ly migraine headache days during the 3-month treatment period in all patients who were randomly assig

179 Patients who completed the 52-week treatment period in an INPULSIS trial could receive open

180 mber and percentage of adverse events in the treatment period in an intention-to-treat analysis.

181 n was 98%, and 86% of subjects completed the treatment period in both groups.

182 V(1) as a percent predicted) over the 4-year treatment period in both main effects and interaction mo

183 9.1 mmol/L (p<0.001) during the combination treatment period in cohort 1.

184 energy x-ray absorptiometry over the 12 week treatment period in eligible patients who had at least o

185 hloride concentration during the combination treatment period in the intention-to-treat population an

186 adout of mTOR activity) was reduced over the treatment period in the responding xenograft but express

187 among placebo patients during the prednisone treatment period in VISUAL-1 was statistically higher th

188 le-blind period entered a 24 week open-label treatment period in which all patients received eltrombo

189 n-in period, subjects were randomized into 3 treatment periods in a crossover clinical trial, with a

190 bo twice daily during two consecutive 14-day treatment periods in a crossover sequence.

191 During the treatment periods in the dose-finding and extension stud

192 per week for at least 9 weeks of the 12-week treatment period including at least three of the last 4

193 At 7 to 14 days after the treatment period, invasive infections had developed in 2

194 The treatment period lasted 24 months from randomisation.

195 Although the 8-week treatment period limits interpretation to acute treatmen

196 During the treatment period, major bleeding occurred in 6 patients

197 During the 24-week treatment period, mean BCVA significantly improved at 0.

198 Over the treatment periods, mean+/-SD LDL cholesterol reductions

199 After the treatment period, mice were euthanized during diestrus,

200 n approximately </=10 g/dL) during the study treatment period (n = 500) were assigned to groups that

201 Serious bleeding during the treatment period occurred in 10 patients in the DrotAA g

202 days (IQR 29-35) in children who had a study treatment period of 1 month (n=37), symptomatic recurren

203 After the treatment period of 28 days, each group was further subd

204 days (IQR 87-95) in children who had a study treatment period of 3 months (n=463) and 31 days (IQR 29

205 Goal BPs were achieved after a median treatment period of 3 to 4 months; at that time, the mea

206 nuing anticoagulant therapy beyond the acute treatment period of 3 to 6 months, evidence-based recomm

207 o <15 per high-power field over a short-term treatment period of 4-12 weeks, but very low certainty a

208 After a treatment period of 5days, IN applied FTA loaded HNPs ac

209 ted ipilimumab (182 [39%] during the initial treatment period of four doses).

210 Patients who completed the 52-week treatment period of INPULSIS, and the follow-up visit 4

211 ant study drug dose, followed by an adjuvant treatment period of up to 1 year.

212 e found to be slightly less effective during treatment periods of 1 to 2 years, but they were associa

213 bjects (n=29) participated in two randomized treatment periods of daily placebo or PF-04958242 for 5

214 greatest average change in BMD during early treatment periods of IAD with a smaller average change t

215 was 3070 before and 4651 after the low-salt treatment period, on average.

216 During the treatment period, one death, one nonfatal stroke, and tw

217 During the treatment period, one patient died in the ixazomib group

218 ous thromboembolism-related death during the treatment period or asymptomatic proximal deep-vein thro

219 ignificantly from baseline to the end of the treatment period (P<0.001).

220 eek thereafter during a 16-week double-blind treatment period (part A).

221 After 6 monthly injections (treatment period), patients meeting prespecified criteri

222 During each 14-day treatment period, patients received balanced doses of an

223 Over the treatment period, patients receiving placebo or bosutini

224 randomized, placebo-controlled, double-blind treatment period, patients with moderate-to-severe psori

225 During the treatment period, patients, investigators, their site pe

226 ry outcomes were the composite at 42 months (treatment period plus 24-month follow-up), as well as ea

227 week if required) for up to 7 years (primary treatment period plus extension phase) or until the prod

228 During the entire treatment period, pooled exposure-adjusted incidence rat

229 ined asthma exacerbations during the 48-week treatment period (primary endpoint).

230 cidence of serious adverse events during the treatment period ranged from 3 to 16% across trial group

231 During the 4-week treatment period, recovery was significantly faster in t

232 , or a thromboembolic event during the trial treatment period; recurrence of TTP at any time during t

233 shorter (6-9-month) or longer (24-30-month) treatment periods relative to subjects' best predose wal

234 products at port facilities due to the short treatment period required, but it is vented from fumigat

235 h between doses and contributing to the long treatment periods required for TB.

236 to estimate the rates of changes during the treatment period.RESULTSThere were 9 drug-related gastro

237 ial resistance was evident at the end of the treatment period (risk ratio 1.91, 1.46 to 2.49; p<0.000

238 double-blind, crossover design (two 24-week treatment periods, separated by a 4-week washout) for 52

239 ind, crossover trial, including two 6-8 days treatment periods, separated by a 6-day washout, and 3 a

240 ion of As concentrations following different treatment periods showed that As accumulation in roots a

241 On day 5 of each treatment period, subjects underwent a ketamine infusion

242 support was significantly higher during the treatment period than at baseline and end of therapy, Z

243 ptom experience deteriorated more during the treatment period than at the baseline, Z >/= -1.97, p </

244 stress were significantly higher during the treatment period than at the end of treatment.

245 re significantly less likely to complete the treatment period than those assigned to the control cond

246 ms of action of adjuvants may advise shorter treatment periods than the current three-to-five-year re

247 Three deaths occurred during the treatment period that were not condsidered to be treatme

248 tralstat in patients with HAE over a 24-week treatment period (the phase 3 APeX-2 trial).

249 erms of absolute risk averaged over a 1-year treatment period, the increase in risk attributable to I

250 During the 18-month treatment period, the primary outcome occurred in 6 of 1

251 After the treatment period, the tumors in all groups grew at simil

252 nt and placebo groups during the combination treatment period; the most commonly reported events were

253 During the treatment period, there were 11 deaths in the metoprolol

254 Four deaths occurred during the 12-week treatment period, three in NightLyte (upper gastrointest

255 During the trial treatment period, three patients in the placebo group di

256 During the 30-week continuation treatment period, time to remission did not differ signi

257 were taken at the beginning and end of each treatment period to determine the effects on HDL composi

258 omparing the HAE attack incidence during the treatment period to the historical attacks over the prev

259 During the first treatment period, treatment with OC000459 significantly

260 eks (n=151), of whom 383 (85%) completed the treatment period up to week 52.

261 studied surface chemistry changes during the treatment period using hematite, a model Fe INP, suspend

262 addition provides lasting benefit beyond the treatment period via enhanced U(VI) adsorption to sedime

263 During the final 9 d of the treatment period, volunteers collected all urine and fec

264 The mean breakthrough attack rate during the treatment period was 0.4 attacks/week (95% CI 0.28-0.56)

265 The acute treatment period was 2 weeks.

266 The maximum treatment period was 2 y or until occurrence of a CRBSI

267 The main treatment period was 3 months (1 month in children <2 ye

268 The median duration of the neoadjuvant treatment period was 5.1 months.

269 e median oxygen saturation at the end of the treatment period was 99% among patients assigned to oxyg

270 reatment on alternate days during a five-day treatment period was able to restore a healthy ocular su

271 The original 3-y treatment period was extended into a subsequent colonosc

272 The 12-week treatment period was followed by a 6-week single-blind p

273 Each buspirone treatment period was followed by saline control treatmen

274 he BCVA gain achieved in the initial 6-month treatment period was maintained with an additional 12 mo

275 Each 4-wk treatment period was separated by 4-wk washout intervals

276 Each treatment period was separated by a 3-4 week washout per

277 e event that occurred or worsened during the treatment period was similar across the trial groups.

278 e of adverse events that occurred during the treatment period was similar in the evolocumab and place

279 t of platelet reactivity at the end of the 2 treatment periods was lower for ticagrelor (32.9 PRU, 95

280 The order of the 2-week treatment periods was randomized, and a 3-week wash out

281 awal symptom score by treatment by full-dose treatment period (weeks 3-12) for drinking days, heavy d

282 oup, 6 of 20 deaths that occurred during the treatment period were considered to be drug-related.

283 oncentrations between yolk and white in post treatment period were found.

284 The mean scores at the end of the 6-week treatment period were lower for the ECT group than for t

285 lth-related quality of life over the 48-week treatment period were observed.

286 on treatment at the end of the double-blind treatment period were offered open-label enzalutamide at

287 d completed the initial 52-week double-blind treatment period were then allowed to enter a 24-week op

288 The treatment periods were followed by a 14-day single-blind

289 Treatment periods were separated by a 14-day washout.

290 rom baseline for >/= 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of

291 older, CEE led to adverse effects during the treatment period, whereas women randomly assigned to CEE

292 il the first exacerbation of COPD during the treatment period, which ranged from 336 to 350 days, dep

293 metformin-alone run-in period, and a 5-year treatment period, which was further split into study per

294 ses, complete resolution occurred within the treatment period with no recurrence for at least 3 month

295 These findings indicate that a prolonged treatment period with raloxifene might be required to pr

296 ion, FR 10 schedule) during continuous 7-day treatment periods with saline or the agonist medication

297 h both vehicle and Restasis over the 16-week treatment period, with an early onset of effect (at day

298 ong the three study groups at the end of the treatment period, with mean scores of 35.0 (95% confiden

299 o <15 per high-power field over a short-term treatment period, with moderate certainty for elemental

300 rs have proven to be well tolerated for long treatment periods, with minimal adverse events, in the o